Scailyte

Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery. Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery. The company is developing AI software for single-cell data analysis to discover novel biomarkers for the early and precise detection of a wide range of complex diseases. This AI-based single-cell technology can also be used for the identification of relevant single-cell patterns from mass cytometry data. Founded in 2017, headquartered in Basel, Switzerland. The company operates in the Life Sciences > Genomics, Native AI > Artificial Intelligence sector. Founded in 2017 and headquartered in Basel, Switzerland and has raised $20.3 million in Series A funding. Key investors include Venturelab, Zurcher Kantonalbank, Swisscom Ventures, MassChallenge, Swisscom, HEMEX, Verve Ventures, Mirabaud.